Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Dennis K. Showers who wrote (17608)	4/24/2006 10:01:33 PM
From: Galirayo	Respond to of 23958

[ALKS] Thanks Dennis .. here's another good reason. Message 22142502

To: Dennis K. Showers who wrote (17608)	4/26/2006 8:50:17 AM
From: Galirayo	Respond to of 23958

Lilly and Alkermes Initiate Additional Phase 3 Study for Inhaled Insulin as Part of Comprehensive Registration Program Wednesday April 26, 8:00 am ET INDIANAPOLIS, Ind. and CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 26, 2006--Eli Lilly and Company (NYSE: LLY - News) and Alkermes, Inc. (Nasdaq: ALKS - News) today announced the initiation of a Phase 3 clinical trial required for registration for their AIR® Inhaled Insulin System(1) (AIR system), which is being investigated as an innovative treatment option for type 1 and type 2 diabetes. This study in type 2 diabetes patients is designed to compare A1C -- an average measure of blood sugar (glucose) over a three-month period -- between the AIR system and injectable pre-meal insulin. The study is part of the comprehensive Phase 3 pivotal program that began in July 2005. biz.yahoo.com